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Abstract
Background:  It has been suggested that intrasphincteric injection of botulinum toxin (BTX) may
represent an alternative therapy to balloon dilatation in achalasia. The aim of the present study was to test
the effectiveness of botulinum toxin injections in achalasia patients, as assessed using lower oesophageal
sphincter pressure (LOSP) and symptom scores, and to compare the response in patients with different
types of pretreatment (no previous treatment, balloon dilatation, myotomy, BTX injection).
Methods: Forty patients who presented with symptomatic achalasia were treated with BTX injection (48
injections in 40 patients). Some of the patients had received prior treatment (seven with myotomy, seven
with dilatation and eight with BTX). The symptoms were assessed using a global symptom score (0–10),
which was evaluated before treatment, 1 week afterwards, and 1 month afterwards. Manometry was also
carried out before and after treatment. Three different selections of patients were studied: all patients;
untreated patients; and patients with prior BTX, dilatation, or myotomy.
Results: After BTX injection, there was a significant reduction in LOSP (before, 38.2 ± 11.3 mmHg; 1
week after, 20.5 ± 6.9 mmHg; 1 month after, 17.8 ± 6.8 mmHg; P < 0.001). The global symptom score and
symptom subscores (dysphagia, regurgitation, chest pain) were significantly decreased after 1 week and 1
month. When the beneficial effects following BTX injection were compared (untreated vs. pretreated),
neither changes in LOSP nor beneficial effects on the symptom scores significantly differed. After 6 months,
67.7% of all treated patients were still in symptomatic remission (subgroups: previously untreated patients,
61.5%, n = 26; prior dilatation, 71.4%, n = 7; prior myotomy, 71.4%, n = 7; prior BTX, 73.9%, n = 8).
Conclusions:  BTX injection offers an alternative treatment for achalasia which is safe and can be
performed in an outpatient setting. The initial response to BTX, in terms of symptom scores and LOSP,
appears to be independent of any prior treatment. A number of patients do not adequately respond to
balloon dilatation or myotomy, which are the first-line treatment modalities in achalasia patients. BTX
injection can be performed in these patients, and symptomatic benefit can be expected in the same
percentages as with BTX injection in untreated patients.
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Background
Achalasia is a primary motility disorder of the oesophagus
that is characterised by impaired opening of the lower
oesophageal sphincter, resulting in delayed oesophageal
emptying [1–3]. Morphologically and pathophysiologi-
cally, achalasia is characterised by an imbalance of excita-
tory and inhibitory neural inputs in the lower
oesophageal sphincter region [4] Thus, it has been dem-
onstrated that the neurons containing the inhibitory neu-
rotransmitters nitric oxide and vasoactive intestinal
polypeptide (VIP) are specifically absent in the sphincter
region [5,6]. Endoscopic ultrasound or computed tomog-
raphy (CT) examinations performed in achalasia patients
often show a thickening of the muscle layers in the lower
oesophageal sphincter (LOS) [7,8].
The optimal treatment for achalasia includes several op-
tions. Pneumatic balloon dilatation of the lower oesopha-
geal sphincter is regarded as the treatment of choice in
these patients; however, balloon dilatation is limited by
success rates of 80–85% and the possibility of oesopha-
geal perforation, which may occur in 1.3–1.5% of cases
[9–12]. In patients with minor or residual post-treatment
symptoms, a trial of calcium antagonists for symptomatic
relief may be offered [13] Surgical treatment (mostly
laparoscopic) with Heller myotomy is recommended for
patients who do not respond to dilatation therapy [14]
Botulinum toxin (BTX), a highly specific toxin, blocks the
release of acetylcholine from cholinergic neurons. It can
be widely used for injection treatment in several gastroin-
testinal disorders, including oesophageal disorders such
as achalasia, [15–17]. Chagas' disease of the oesophagus
[18] and non-achalasic oesophageal motility disorders
such as hypertensive LOS and diffuse oesophageal spasm
[19,20]. In comparison with a placebo injection of saline,
BTX leads to significant symptomatic and clinical im-
provement, as well as a reduction in the oesophageal di-
ameter, LOS pressure and oesophageal emptying time in
achalasia patients [17] However, the mechanism of action
and the initial results suggest that one major disadvantage
of BTX injection therapy is a gradual waning of its effect,
with symptoms recurring after an average of 6–8
months.29 While there is some concern that BTX injection
may interfere with subsequent myotomy, no data are
available on the influence of pretreatment on the out-
come of BTX therapy.
It has previously been shown that intrasphincteric injec-
tion of botulinum toxin can be used in the treatment of
achalasia, leading to an improvement of clinical symp-
toms and objective parameters, [15,17] and this finding
has been confirmed by several other groups [17,21–27].
Balloon dilatation and myotomy are the accepted first-
line treatments for achalasia patients. The two modalities
have long-term failure rates of 15–20% for balloon dilata-
tion and 10–15% for myotomy. BTX treatment, on the
other hand, is hampered by a nearly 100% failure rate
over time, although some patients may show a prolonged
clinical response for more than 6 months after a single in-
jection [17,22,28].
The aim of the present study was to evaluate whether pre-
treatment of any kind affects the symptomatic short-term
and long-term outcome, or the reduction in LOSP, after
BTX injection.
Methods
Consecutive patients with symptomatic achalasia referred
to the Second Department of Internal Medicine at the
Technical University of Munich between January 1994
and April 1999 were included in the study, and were pro-
spectively followed up in a prospective open protocol. All
patients included in the study had the characteristic clini-
cal, radiographic and manometric features of achalasia. At
their first diagnostic evaluation, all patients underwent ex-
tensive biopsies of the cardia region, as well as either en-
dosonography or CT scanning of the cardia region, to rule
out secondary achalasia. Exclusion criteria were oesopha-
geal varices, peptic complications (stricture, Barrett's
oesophagus) and extra-oesophageal malignant disease.
All of the procedures, as well as the functional studies,
were performed after written consent had been obtained
from the patients; the study protocol was approved by the
Ethics Committee of the Technical University of Munich.
Study design
All patients underwent a pretreatment assessment consist-
ing of oesophageal manometry, upper gastrointestinal en-
doscopy and barium swallow. After the patients had been
provided with extensive information regarding the two
endoscopic treatment options and regarding myotomy,
the decision on which treatment would be used was made
according to each patient's preference.
At admission, 1 week, 1 month and then every 6 months
after therapy, all patients were evaluated clinically on an
outpatient basis or by telephone interview. A manometric
evaluation of treatment success was made 7–10 days and
1 month after therapy.
Clinical assessment
The overall clinical assessment (global symptom score)
was made using an analogue scale ranging from 0 (no
symptoms) to 10 (intolerable), carried out immediately
before treatment and then 1 week and 1 month after-
wards. In addition, the presence of the symptoms regurgi-
tation, dysphagia and chest pain was evaluated and scoredBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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as 0 (none), 1 (occasional), 2 (daily), or 3 (with each meal
or constantly) [17] A global symptom score of less than or
equal to 3 was regarded as representing clinical remission.
All patients were also questioned regarding symptoms in-
dicating possible complications of the treatment, such as
chest pain, fever, weakness of the muscles, phonation
problems, and reflux symptoms.
Subsequently, the patients were contacted every 6 months
and re-evaluated for the presence of clinical symptoms. In
addition, the patients were asked to report to the centre if
any additional symptoms occurred during this period.
Oesophageal manometry
Oesophageal manometry was carried out, after the pa-
tients had fasted overnight, using a low-compliance per-
fusion system with a pneumohydraulic perfusion pump
(Mui Scientific, Mississauga, Ontario, Canada), with a
minimum pressure rise rate of 300 mmHg/s and a stand-
ard four-channel manometric catheter with the manomet-
ric ports spaced 5 cm apart. The manometric tracings were
recorded by a PC Polygraph system (Synectics Medical,
Frankfurt, Germany). Manometry was performed using
the stationary pull-through method, with the catheter in-
troduced transnasally into the stomach. In patients in
whom direct placement was not possible, the manometric
tube was advanced into the stomach endoscopically, and
the measurements were carried out 2–3 h later.
The lower oesophageal sphincter pressure was recorded
during the stationary pull-through with all recording sites,
and the mean value was used to represent lower oesopha-
geal sphincter pressure; swallowing-induced relaxation
was also tested. Ten swallows of 5 mL water were used to
determine the oesophageal motility and the LOS relaxa-
tion; the contraction amplitude, duration and propaga-
tion velocity were determined when possible.
Endoscopic injection of btx
For endoscopic injection of BTX, the toxin was dissolved
in 5 mL of saline. Botulinum toxin A (Botox®, 100 IU) was
dissolved in 5 mL (20 IU/mL). The position of the lower
oesophageal sphincter was identified endoscopically by
visualisation of the Z-line and the typical narrow segment
of the cardia region. The BTX was injected in 1-mL por-
tions using a 7-mm injection needle in all four quadrants
of the LOS, in a prograde fashion. The average time need-
ed for the injection procedure was 4.5 min (range 1.5–8.5
min), not including the time needed for cleaning retained
food or fluid out of the oesophagus. The procedure was
carried out during a 1-day hospital stay in the first nine pa-
tients, and on an outpatient basis with the subsequent pa-
tients. No radiographic monitoring was used, and the
patients were allowed to eat after 2 h when the sedation
had worn off. All BTX injections were carried out by a sin-
gle investigator (H.D.A.).
Statistical analysis
Statistical analysis was conducted using the Wilcoxon test
and paired Student's t-test to compare the effect of Btx in-
jection on the patients' symptoms scores or lower
oesophageal pressure at the various time points. Differ-
ences between previously untreated patients and those
who had undergone prior treatment were checked for sta-
tistical differences, using the Mann-Whitney test or un-
paired Student's t-test. A P value of less than 0.05 was
considered to be significant. All statistical analyses were
carried out using the Statistical Package for the Social Sci-
ences (SPSS) for Windows programme, version 10.1.
Results
Forty patients (25 men, 15 women) with a mean age of 48
± 17.3 years, were included in the study; the patient data
are shown in table 1. Seven patients had undergone prior
treatment with pneumatic dilatation before inclusion in
the study, and seven patients had received a myotomy be-
fore.
Evaluation of the clinical course
BTX injection was carried out in the 40 patients after they
had provided written consent (26 patients with newly di-
agnosed achalasia, seven patients with long-term failure
of myotomy, seven patients with failure of dilatation).
Eight patients in whom BTX injection failed in the shorter
or longer term during the study were re-treated with BTX
injection, leading to a total of 48 BTX injection procedures
during the follow-up period.
When all first injections are taken into account, without
regard to prior treatment, 31 of the 40 patients (77.5%)
were in clinical remission 3 months after a single injec-
tion. After 6 months, 26 of the 40 patients (66.7%) were
still in remission after a single injection. When repeat in-
jections during the clinical course are taken into account,
31 of the 40 patients (77.5%) were still in remission after
6 months.
Table 1: Summary of the pretreatment patient characteristics, 
clinical symptoms, treatments and lower oesophageal sphincter 
pressure in patients treated with intrasphincteric injection of 
botulinum toxin
Patients (n) 40
Mean age (range) 48.1 ± 17.3 (18–76)
Male/female 25/15
Body weight (kg) 74.0 ± 18.9
Number of procedures 48 (single 32, repeat 8)
Median symptom score (1–10) 8
Median regurgitation score (0–3) 2
Median dysphagia score (0–3) 3
Median chest pain score (0–3) 2
Mean lower oesophageal pressure (mmHg) 38.2 ± 11.1BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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When multiple injections are taken into account, injec-
tion of botulinum toxin led to a good clinical short-term
response (4 weeks; global symptom score <3) in 89.7% of
the patients. The first BTX injection failed after 4 weeks
with in five injections, and after 6 months in eight injec-
tions. Four patients in whom injection therapy initially
failed (no symptomatic benefit, or benefit for less than 4
weeks) received a repeat injection, and two of the four re-
sponded to the repeated treatment.
When all first injections in previously untreated achalasia
patients are analyzed, 22 of 26 patients showed a good
clinical short-term response after 1 month (84.6%); 19 of
the 26 patients still had a good result after 3 months
(73%); and 16 of the 26 patients still had no need for re-
peat treatment after 6 months (61.5%) following a single
injection.
In the seven patients who had previously received dilata-
tion treatment, three had had dilatation 1.5, 2, or 5 years
before presentation at our department, and the dilatation
procedure had failed at other hospitals in four patients.
After BTX injection, six of the seven patients in this group
experienced clinical remission for more than 3 months
(85.7%), and five had clinical remission for more than 6
months (71.4%).
Seven patients in whom myotomy had failed were includ-
ed in the study. Five of these seven patients were in remis-
sion 3 months after the BTX injection (71.4%), and all five
were still in remission after 1 year (71.4%). One patient
with initial treatment failure received a second injection,
which was once again a failure, and one patient received a
repeat injection after a period longer than 1 year.
Evaluation of the symptom score and lower oesophageal 
sphincter pressure
Symptom scores (global symptom score; symptom scores
for dysphagia, regurgitation and chest pain) and lower
oesophageal sphincter pressures were evaluated for each
individual patient before the injection, as well as after 1
week and 1 month.
When all first injections of BTX (n = 40) are evaluated,
there was a significant reduction in the median clinical
symptom score (before, 8; 1 month after, 3; Wilcoxon test
P < 0.001) and in the median symptom scores for regurgi-
tation (before, 2; after 1 month, 1; P < 0.001), dysphagia
(before, 3; after 1 month, 1; P < 0.001), chest pain (before,
2; after 1 month, 1; P < 0.01) (fig. 1A,1B,1C,1D). In the
successful cases, the symptomatic response to the BTX in-
jection was accompanied by a reduction in lower
oesophageal sphincter pressure; the mean of the lower
oesophageal sphincter pressures decreased from 38.2 ±
11.1 mmHg to 20.5 ± 6.7 mmHg 1 week after injection
and to 17.8 ± 6.8 mmHg 1 month after injection (paired
t-test: P < 0.001) (fig. 2).
There was no significant difference in the clinical response
to BTX injection among patients (n = 14) who had re-
ceived treatment prior to the study, in comparison with
previously untreated achalasia patients who received BTX
as the first treatment (n = 26) (table 2). Five of the seven
patients with prior dilatation showed an excellent re-
sponse to botulinum toxin injection (mean symptom-free
interval 797 days), whereas two showed only short clini-
cal responses (43 and 97 days). The patient with a 43-day
initial response showed a good clinical response to a sec-
ond injection (more than 1 year), whereas the other pa-
tient failed to respond to a second injection.
Sixteen of the 40 patients needed one or more repeat in-
jections during the long-term course of the study (23 in-
jections). When the symptom scores for the re-treated
patients were evaluated, no significant difference was
found in comparison with the group of first injections in
previously untreated achalasia patients (table 3).
There were no serious complications or side effects of BTX
injection. There were four episodes of chest pain that last-
ed for up to 4 h after injection, which resolved spontane-
ously and did not require medical treatment. No other
side effects were observed.
Discussion
The present study included consecutive patients with
symptomatic primary achalasia. The patients were includ-
ed independently of any prior treatment they had received
(such as myotomy or balloon dilatation), and underwent
BTX injection into the lower oesophageal sphincter. In the
study, an injection of 100 IU Botox® into the lower
oesophageal sphincter was used. A number of investiga-
tions have focused on the optimal dosage of BTX, and 80–
100 IU BTX is currently regarded as the optimal dose.
With Botox®, the dosage of BTX can even be reduced to 50
U, as shown in a preliminary report in 23 patients who
were randomly assigned to injection treatment with either
50 U or 100 U of BTX [29] There was a similar rate of treat-
ment success (five of 10 vs. seven of 13) in the two groups;
however, the mean duration of the clinical response was
longer in patients treated with 100 U in comparison with
those receiving 50 U (7 months vs. 3.4 months), indicat-
ing that 100 IU Botox® may be the optimal dosage [29]
The present investigation focused on the response to BTX
injections in different patient groups. When all first injec-
tions are taken into account, the patients showed a good
clinical short-term response, in 77.5% after the 3-month
evaluation. In the longer term, after 6 months, 66.7%
were still in clinical remission after a single injection; andBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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when repeat injections are included, 89.7% of the patients
were in remission after 6 months. These findings are in
agreement with those of other investigators who have re-
ported comparable success rates. In the shorter term, re-
ported success rates have ranged from 70% to 90%
[16,17,21,22,27,30]. For the longer-term results after 6
months, including multiple injections, the published suc-
cess rates range from 44% up to 90%, and the long-term
success rates in the present study lie well within this range
[16,17,21,22,27,30].
Figure 1
Box plots demonstrating the influence of botulinum toxin injection therapy after 1 week and 1 month on (A) symptom score,
(B) dysphagia, (C) regurgitation and (D) chest pain.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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Anecdotal reports in the literature have suggested a detri-
mental effect of preliminary procedures – either pneumat-
ic dilatation or botulinum toxin treatment – on the
outcome of surgical Heller myotomy. A retrospective
study of 44 patients, including 18 patients who received
pneumatic dilatation and 10 patients who received botu-
linum toxin before pneumatic dilatation, or in whom bot-
ulinum toxin injection initially failed, found that these
preliminary procedures did not affect the results of myot-
omy in terms of outcome or complications [31] An in-
crease in the complication rate (50% with perforation)
and a fibrotic lower oesophageal sphincter were observed
only in a small subgroup of four patients in whom botu-
linum toxin injection initially failed [31] Another investi-
gation analysing 15 patients receiving myotomy after
prior BTX treatment reports on difficulties in dissection of
the submucosal plane in 8 of the 15 patients and a perfo-
ration in 2 of the 15 patients (13,3%) which is a signifi-
cant higher perforation rate than the perforation rate
observed in patients without prior BTX treatment.21 How-
ever, these findings were not confirmed in a retrospective
study of 92 patients, with results published in 1999 and
2000, including 22 patients who received pneumatic dila-
tation and 10 patients who received botulinum toxin.
These studies did not demonstrate increased complica-
tions or a poorer outcome in the pretreated group than in
the previously untreated group [32,33]. The authors did
not report finding any fibrotic changes in the lower
oesophageal sphincter or increased complication rates
among patients who had received prior treatment with
botulinum toxin [32,33].
To evaluate possible influences of prior treatment on the
success rates of endoscopic botulinum toxin injections, a
subgroup analysis in consecutively treated achalasia pa-
tients was carried out in the present study. The groups in-
cluded previously untreated patients and patients with
prior myotomy, prior balloon dilatation, or prior BTX in-
jection. There were no significant differences between the
various subgroups of patients with regard to the sympto-
matic response in the global symptom score, or in terms
of subscores for dysphagia, regurgitation and chest pain,
or in the LOSP assessments before treatment and 1 week
and 1 month after BTX injection. On the basis of these
findings, the short-term response to BTX injection into the
lower oesophageal sphincter in patients with achalasia ap-
pears to be independent of any prior treatment. BTX injec-
tions can be repeated when the effects of the initial
injection decline, and the response to a second injection
is comparable to the response in previously untreated pa-
tients. A few reports of achalasia patients with prior treat-
ment have occasionally been included in BTX injection
studies, and the symptomatic response in these patients
has been described as comparable to that in previously
untreated patients. Annese et al. reported on two patients
with prior myotomy and three patients with prior dilata-
tion who responded well to BTX injection when the global
symptom score and LOS pressure were evaluated after 1
month and 6 months. However, this group of patients is
too small to allow statistical comparison with the results
achieved in previously untreated patients [26]
Pneumatic dilatation and myotomy are currently the two
acceptable long-term treatments for oesophageal achala-
sia. Heller myotomy, either open or laparoscopic, has a
success rate of 85–90%. Treatment failures with myotomy
constitute a considerable therapeutic problem. Pneumatic
balloon dilatation is still the treatment of choice for pa-
tients with achalasia, with an overall efficacy rate for excel-
lent or good long-term results of 80–85%. Whereas
retrospective studies have shown that myotomy and
pneumatic dilatation are equally effective, randomised
prospective studies have found that pneumatic dilatation
is superior to botulinum toxin injection, since patients
treated with botulinum toxin need regular repeat treat-
ments during the further course. From the point of view of
cost-effectiveness, pneumatic dilatation is superior to
both myotomy [34] and botulinum toxin injection [30]
The overall complication rate with pneumatic balloon dil-
atation (3%) is higher than that with botulinum toxin in-
Figure 2
Mean (95% confidence interval) lower oesophageal sphincter
pressure before BTX injection and 1 week and 1 month
afterwards in previously untreated patients (n = 26) and in
patients with previous treatment for achalasia (n = 14). Note
that there is a significant reduction in the LOS pressure in
the two groups, independent of previous therapyBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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jection, for which – with the exception of one case report
of a fatal heart block in a patient with previously known
cardiac arrhythmia [35] – no serious complications have
so far been reported.
In studies by several groups, intrasphincteric injection of
BTX has been shown to be an alternative treatment for
achalasia. However, the indication for this treatment is
still questionable, since in the literature most patients
treated with BTX have required some form of repeat treat-
ment during the further course, mainly involving dilata-
tion or myotomy. On the basis of the present study, BTX
injection could be recommended as an alternative treat-
ment – especially in older patients, patients who are at in-
creased risk in dilatation treatment, or those in whom
other treatment modalities have failed. A small number of
patients have a good and prolonged response after a single
BTX injection, without need for further treatment. Taking
into account the long-term efficacy and the increasing
costs due to the frequent necessity of repeat treatment,
BTX injection therapy can only be regarded as an alterna-
tive in a minority of patients, such as those who are at in-
creased risk with other modalities (such as dilatation and
myotomy). However, treatment failure is a significant risk
with pneumatic dilatation and myotomy. In these pa-
tients, BTX injection can be used without loss or reduction
of efficacy.
Conclusions
In conclusion, though the number of patients is low this
study shows that the short-term effects of BTX injection in
patients with symptomatic achalasia seem to be inde-
pendent of any possible prior treatment (no previous
treatment, myotomy, dilatation, or BTX). This is based on
Table 2: Lower oesophageal sphincter pressure (LOSP) at various time points in previously untreated and pretreated patients with 
achalasia
Previously untreated (n = 26) 
mmHg
Pretreated (n = 14) 
mmHg
P (unpaired t-test)
Prior BTX 38.7 ± 12.9 37.1 ± 6.6 NS
1 week after BTX 21.3 ± 6.9 18.8 ± 6.8 NS
1 month after BTX 18.5 ± 7.3 16.4 ± 5.6 NS
Numbers are mean values ± SD. BTX, botulinum toxin; NS, not significant (P > 0.05)
Table 3: Symptom scores at various time points in previously untreated and pretreated patients with achalasia
Previously untreated (n = 26) Pretreated (n = 14) P (Mann-Whitney 
test)
Global symptom score (0–10)
Before BTX 8.5 (6–10) 8 (7–10) NS
1 week after BTX 3 (0–7) 3 (1–7) NS
1 month after BTX 2 (0–7) 3 (1–7) NS
Dysphagia score (0–3)
Before BTX 2.5 (1–3) 3 (2–3) NS
1 week after BTX 1 (0–3) 1 (0–3) NS
1 month after BTX 1 (0–3) 1 (0–3) NS
Regurgitation score (0–3)
Before BTX 2 (0–3) 2 (1–3) NS
1 week after BTX 0 (0–2) 1 (0–2) NS
1 month after BTX 0 (0–1) 1 (0–2) NS
Chest pain score (0–3)
Prior BTX 2 (0–3) 2 (0–3) NS
1 week after BTX 1 (0–3) 1 (0–2) NS
1 month after BTX 0 (0–3) 1 (0–2) NS
Numbers are medians (min-max). NS, not significant (P > 0.05)BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/19
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manometric evaluation of the LOS pressure, as well as on
the evaluation of the symptom scores. BTX injection ther-
apy can be offered to patients after failure of the first-line
treatment options of balloon dilatation and myotomy,
and the symptomatic benefit after BTX injections lies
within the range of beneficial effects in patients who have
not received any prior treatment.
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